SCHEMBL5056419

SCHEMBL5056419

CCOC(=O)c1ccc2c(c1)/C(=C/CCN(C)C)c1ccccc1CO2

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 4/20 0.65
▸ LMNA P02545 2/20 0.65
▸ KCNH2 Q12809 2/20 0.62
▸ HTR2B P41595 2/20 0.62
▸ SLC22A1 O15245 1/20 0.62
▸ CHRM2 P08172 1/20 0.62
▸ CHRM4 P08173 1/20 0.62
▸ HTR1A P08908 1/20 0.62
▸ CHRM5 P08912 1/20 0.62
▸ ADRA2A P08913 1/20 0.62
▸ CHRM1 P11229 1/20 0.62
▸ DRD2 P14416 1/20 0.62
▸ ADRA2B P18089 1/20 0.62
▸ ADRA2C P18825 1/20 0.62
▸ CHRM3 P20309 1/20 0.62
▸ DRD1 P21728 1/20 0.62
▸ DRD4 P21917 1/20 0.62
▸ DRD5 P21918 1/20 0.62
▸ SLC6A2 P23975 1/20 0.62
▸ HRH2 P25021 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5064807 1.00 HRH1 (0.65) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL9749424 1.00 HRH1 (0.65) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL30783267 0.90 HRH1 (0.67) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL5060455 0.90 HRH1 (0.67) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL9749546 0.90 HRH1 (0.67) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL5066512 0.90 HRH1 (0.67) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL9749916 0.87 HRH1 (0.74) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL5056578 0.87 HRH1 (0.74) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL5056536 0.87 HRH1 (0.74) HRH1LMNAKCNH2HTR2BSLC22A1
SCHEMBL5056588 0.87 HRH1 (0.74) HRH1LMNAKCNH2HTR2BSLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139531-A1 USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR ALCON MANUFACTURING LTD. (US) 2008-06-12 — — US claimed
US-20080139531-A1 USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR ALCON MANUFACTURING LTD. (US) 2008-06-12 — — US disclosed
US-5116863-A Antiallergens, antiinflammatory agents; asthma KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139531-A1 USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR CMA1, LTK, KIT HRH1 35/4885LMNA 3550/4885KCNH2 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback